Document is current
Any future updates will be listed below
-
Authors
Belabed, Meriem https://orcid.org/0000-0002-3210-1581
Park, Matthew D.
Blouin, Cédric M. https://orcid.org/0000-0003-0800-0948
Balan, Sreekumar https://orcid.org/0000-0002-2092-5145
Moon, Chang Y.
Freed, Grace
Quijada-Álamo, Miguel
Peros, Ante
Mattiuz, Raphaël https://orcid.org/0000-0002-3292-1635
Reid, Amanda M.
Yatim, Nader
Boumelha, Jesse
Azimi, Camillia S.
LaMarche, Nelson M.
Troncoso, Leanna https://orcid.org/0000-0003-2529-9267
Amabile, Angelo
Le Berichel, Jessica
Chen, Steven T.
Wilk, C. Matthias https://orcid.org/0000-0001-5429-7143
Brown, Brian D. https://orcid.org/0000-0002-3670-8778
Radford, Kristen J. https://orcid.org/0000-0001-6512-6323
Ghosh, Sourav https://orcid.org/0000-0001-5990-8708
Rothlin, Carla V. https://orcid.org/0000-0002-5693-5572
Yvan-Charvet, Laurent https://orcid.org/0000-0002-7748-4942
Marron, Thomas U. https://orcid.org/0000-0001-5903-8191
Puleston, Daniel J. https://orcid.org/0000-0002-8437-0732
Wagenblast, Elvin https://orcid.org/0000-0002-0709-2759
Bhardwaj, Nina https://orcid.org/0000-0003-1865-4187
Lamaze, Christophe https://orcid.org/0000-0001-5430-2707
Merad, Miriam https://orcid.org/0000-0002-4481-7827
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA254104, R01CA277479, U01CA282114)
- License Information
-
More Information
Article History
Received: 2 December 2023
Accepted: 10 December 2024
First Online: 21 January 2025
Competing interests
: M.M. serves on the scientific advisory board of and holds stock from Compugen, Dynavax, Innate Pharma, Morphic Therapeutics, Asher Bio, Dren Bio, Nirogy, Genenta, OncoResponse and Owkin. M.M. serves on the ad hoc scientific advisory board of DBV and Genentech and on the foundation advisory board of Breakthrough Cancer. M.M. receives funding for contracted research from Genentech, Regeneron and Boehringer Ingelheim. M.M. is listed as an inventor on a patent application (16/092576) submitted by the Icahn School of Medicine at Mount Sinai that covers the use of multiplex immunohistochemistry to characterize tumors and treatment responses. The technology is filed through the Icahn School of Medicine at Mount Sinai and is currently unlicensed. This technology was used to evaluate tissue in this study, and the results could impact the value of this technology. T.U.M. has served on advisory and/or data safety monitoring boards for Rockefeller University, Regeneron Pharmaceuticals, AbbVie, Bristol Meyers Squibb, Boehringer Ingelheim, Atara, AstraZeneca, Genentech, Celldex, Chimeric, Glenmark, Simcere, Surface, G1 Therapeutics, NGM Bio, DBV Technologies, Arcus and Astellas and has research grants from Regeneron, Bristol Myers Squibb, Merck and Boehringer Ingelheim. The remaining authors declare no competing interests.
